According to the Zhitong Finance App, Nanxin Pharmaceutical (688189.SH) disclosed its 2023 annual report. The company achieved revenue of 745 million yuan during the reporting period, an increase of 6.55% over the previous year. Net profit attributable to shareholders of listed companies was 3.7515 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 11.0774 million yuan, turning a loss into a profit over the previous year. Basic earnings per share were 0.0137 yuan/share.

During the reporting period, due to factors such as several large-scale outbreaks of respiratory diseases, especially influenza, during the year, the company's sales volume of antiviral drugs increased; at the same time, the company adjusted and optimized sales strategies in a timely manner according to external environment and market changes, increased product sales efforts, and increased market share, and the company's revenue remained steady and increasing. The company continued to promote many measures such as cost reduction and efficiency and achieved good results. The period expenses such as sales expenses, management expenses, and financial expenses all showed a certain decline compared to the same period last year, leading to an improvement in the company's operating performance compared to last year.